The pharma group is paying CHF 450 million (around $507 million) for the privately-held biotech, which was formed to develop a platform that uses live bacteria to deliver therapeutic, immune ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Oncolytic adenovirus was engineered for the forced ectopic delivery of peptide-MHC ligand of T cell receptors (TCRs) to ...

Here, BiomX is targeting at chronic pulmonary infections caused by Pseudomonas aeruginosa bacteria in cystic fibrosis patients. The nano-cap biotech was trading down 8% premarketing Monday morning.

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr.’s shake-up of the nation’s health agencies and persistently high ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

As per Vantage Market Research, the Global Pharmaceutical Sterility Testing Market has been significantly growing over the ...